The purpose of this study is to determine the maximum tolerated dose (MTD) of 5-FU in the presence of doses of BAU determined in a previous phase I trial of elevate plasma uridine concentrations 4-fold in sustainable manner over 48 hours. The MTD will be determined for previously treated and chemotherapy-naive patients. Pharmacokinetic studies of both drugs will be performed. This is a phase I study and measurable of evaluable disease will not be required for enrollment, but response and response duration data will be obtained if appropriate.
Showing the most recent 10 out of 343 publications